CIT’s Virginia Founders Fund Invests in Techulon to Advance the Development of Targeted Antibiotics

​Startup is developing targeted solutions for targeted diseases to address antibiotic resistance, one of today’s biggest threats to global health

---

​“Techulon is advancing a new generation of therapeutics with broad application based on technology that is highly selective of disease targets. This results in more effective drugs that exhibit fewer side effects to patients,” said Tom Weithman, Managing Director of CIT GAP Funds and Virginia Founders Fund. “The startup has already demonstrated the benefits of this targeted approach and is working towards human proof-of-concept studies and translating these findings into clinical applications. We look forward to being part of Techulon’s success.”

---

​http://www.globenewswire.com/news-release/2020/08/31/2086350/0/en/CIT-s-Virginia-Founders-Fund-Invests-in-Techulon-to-Advance-the-Development-of-Targeted-Antibiotics.html